Revolution Medicines (RVMD) Other Non-Current Assets (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Other Non-Current Assets of $14.5 million for Q1 2026, up 10.26% year-over-year from $13.1 million in Q1 2025, and down 2.03% quarter-over-quarter from $14.8 million in Q4 2025.
Revolution Medicines (RVMD) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Revolution Medicines' Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $14.5 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 10.26% year-over-year to $14.5 million; the TTM figure through Mar 2026 stood at $14.5 million (up 10.26% YoY), while the FY2025 annual figure was $14.8 million, up 748.39% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $14.5 million, down from $14.8 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $14.9 million in Q3 2025, with the low at $725000.0 in Q2 2022.
- The 5-year median for Other Non-Current Assets is $3.0 million (2024), against an average of $6.0 million.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets soared 1226.17% in 2023, then plunged 75.23% in 2024.
- Revolution Medicines' Other Non-Current Assets stood at $2.9 million in 2022, then soared by 146.13% to $7.0 million in 2023, then slumped by 75.23% to $1.7 million in 2024, then surged by 748.39% to $14.8 million in 2025, then dropped by 2.03% to $14.5 million in 2026.
- Business Quant data shows RVMD's Other Non-Current Assets at $14.5 million in Q1 2026, $14.8 million in Q4 2025, and $14.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 29.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.45 Mn |
| Mar 31, 2026 | 14.48 Mn |
| Dec 31, 2025 | 14.78 Mn |
| Sep 30, 2025 | 14.87 Mn |
| Jun 30, 2025 | 3.92 Mn |
| Mar 31, 2025 | 13.13 Mn |
| Dec 31, 2024 | 1.74 Mn |
| Sep 30, 2024 | 2.89 Mn |
| Jun 30, 2024 | 3.03 Mn |
| Mar 31, 2024 | 4.16 Mn |
| Dec 31, 2023 | 7.03 Mn |
| Sep 30, 2023 | 11.35 Mn |
| Jun 30, 2023 | 2.59 Mn |
| Mar 31, 2023 | 1.74 Mn |
| Dec 31, 2022 | 2.86 Mn |
| Sep 30, 2022 | 856,000.00 |
| Jun 30, 2022 | 725,000.00 |
| Mar 31, 2022 | 1.74 Mn |
| Dec 31, 2021 | 1.74 Mn |
| Sep 30, 2021 | 1.08 Mn |